ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fulvestrant

Also written as “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, “fulvestrant” and “faslodex 500mg”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Carcinoma, Intraductal, Noninfiltrating · Puberty, Precocious · Endometrial Neoplasms, led by 5 companies.

Drug pageFulvestrant: every studyMany companies study it; this page follows only the 25 they lead. All 122 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 4, 201525 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca211 open or runningphase 4since May 4, 2015Jul 21, 2003none ahead
Atossa Therapeuticsits history only10 open or runningphase 2since Aug 28, 2015Aug 28, 2015none ahead
Criteriumits history only11 open or runningphase 2since Sep 3, 2020Sep 3, 2020Dec 31, 2027phase 2 · NCT04567420
Eagle Pharmaceuticalsits history only10 open or runningphase 1since Oct 24, 2017Oct 24, 2017none ahead
Fresenius Kabiits history only10 open or runningphase 1since May 30, 2016May 30, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jul 21, 2003.

  1. Nov 20, 2005Phase 3 study in Breast NeoplasmsNCT00256698 · 514 enrolled · Canada, Costa Rica, Finland and more
  2. Nov 25, 2005Phase 2 study in Breast NeoplasmsNCT00259090 · 120 enrolled · United Kingdom
  3. Jan 4, 20063 phase 2 studiesNCT00272740, NCT00274469, NCT00278915
  4. Mar 20, 2006Phase 2 study in Breast NeoplasmsNCT00305448 · 143 enrolled · Japan
  5. Apr 10, 2006Phase 2 study in Breast NeoplasmsNCT00313170 · 144 enrolled · Belgium, Canada, Czechia and more
  6. May 18, 2006Phase 1 study in Advanced Breast CancerNCT00328120 · 20 enrolled · Japan
  7. May 18, 2006Phase 3 study in Advanced Breast CancerNCT00327769 · 234 enrolled · China
  8. Jun 5, 2006Phase 2 study in Endometrial NeoplasmsNCT00334295 · 35 enrolled · Germany
  9. Jul 20, 2006Phase 2 study in Breast NeoplasmsNCT00357110 · 13 enrolled · Austria, Germany, Norway
  10. Mar 7, 2008Phase 3 study in Advanced Breast CancerNCT00635713 · 588 enrolled
  11. Jul 22, 2009Phase 3 study in Breast NeoplasmsNCT00944918 · 25 enrolled · Korea, Republic of
  12. Feb 17, 2011Phase 3 study in Breast NeoplasmsNCT01300351 · 249 enrolled · China
  13. May 11, 2012Phase 3 study in NeoplasmsNCT01602380 · 462 enrolled · United States, Argentina, Brazil and more
  14. May 4, 2015Phase 4 study in Breast NeoplasmsNCT02447328 · 83 enrolled · Korea, Republic of

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha antagonist; Estrogen receptor degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 21 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02447328Breast Neoplasms · Korea, Republic of4CompletedMay 6, 201683
NCT01602380Neoplasms · United States, Argentina, Brazil and more3CompletedApr 11, 2016462
NCT01300351Breast Neoplasms · China3CompletedMar 2014249
NCT00944918Breast Neoplasms · Korea, Republic of3CompletedJun 201125
NCT00635713Advanced Breast Cancer3Completed588
NCT00357110Breast Neoplasms · Austria, Germany, Norway2CompletedOct 200813
NCT00334295Endometrial Neoplasms · Germany2CompletedJan 201135
NCT00328120Advanced Breast Cancer · Japan1CompletedApr 200620
NCT00327769Advanced Breast Cancer · China3Completed234
NCT00313170Breast Neoplasms · Belgium, Canada, Czechia and more2CompletedJun 13, 2008144
NCT00305448Breast Neoplasms · Japan2CompletedMar 2008143
NCT00278915Puberty, Precocious · United States, France, Germany and more2CompletedDec 8, 200930
NCT00274469Breast Neoplasms · United States, Brazil, Bulgaria and more2CompletedJan 10, 2008205
NCT00272740Breast Neoplasms · Belgium, Switzerland2Completed93
NCT00259090Breast Neoplasms · United Kingdom2CompletedOct 2008120
NCT00256698Breast Neoplasms · Canada, Costa Rica, Finland and more3CompletedApr 2009514
NCT00241449Breast Neoplasms · United States, Argentina, Australia and more3CompletedMar 200751
NCT00234403Breast Neoplasms · Spain2Completed60
NCT00099437Breast Neoplasms · United States, Belgium, Brazil and more3Active, not recruitingFeb 27, 2009736
NCT00093002Breast Neoplasms · United States, Austria, Brazil and more2Completed179
NCT00065325Breast Neoplasms · United States, Argentina, Belgium and more3CompletedJun 2006694

How it is read

Names in the registry

  • “Fulvestrant”, 26 entries
  • “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
  • “fulvestrant”, 2 entries
  • “faslodex 500mg”, 1 entry
  • “Fulvestrant injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.